Stockscreener 앱 받기
11.22
0.71%
-0.08
전일 마감가:
$11.30
열려 있는:
$11.6
하루 거래량:
752.23K
Relative Volume:
1.20
시가총액:
$677.55M
수익:
-
순이익/손실:
$-117.99M
주가수익비율:
-5.2437
EPS:
-2.1397
순현금흐름:
$-79.92M
1주 성능:
+2.00%
1개월 성능:
-60.03%
6개월 성능:
-42.40%
1년 성능:
-42.40%
1일 변동 폭
$10.88
$11.77
1주일 범위
$10.88
$11.77
52주 변동 폭
$10.52
$34.48
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
11.22 | 677.55M | 0 | -117.99M | -79.92M | -2.1397 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-19 | 개시 | JP Morgan | Overweight |
| 2025-08-27 | 개시 | Needham | Buy |
| 2023-12-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-10-05 | 개시 | Stifel | Buy |
| 2023-06-14 | 개시 | BofA Securities | Buy |
| 2023-06-12 | 개시 | H.C. Wainwright | Buy |
| 2023-06-08 | 개시 | Robert W. Baird | Outperform |
| 2023-05-10 | 개시 | Pareto | Buy |
| 2023-04-28 | 개시 | Wedbush | Outperform |
모두보기
Oculis Holding Ag 주식(OCS)의 최신 뉴스
(OCS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Oculis Holding AG (OCS) Institutional Confidence - TradingKey
Oculis Holding AG (OCS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oculis Holding AG (OCS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oculis Holding AG (OCS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oculis Holding AG (OCS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oculis Holding AG (OCS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oculis Holding AG (OCS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oculis Holding AG (OCS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oculis Holding AG (OCSAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oculis Holding AG (OCSAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oculis Holding AG (OCSAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oculis Holding AG (OCSAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oculis Holding AG (OCSAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oculis Holding AG (OCSAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oculis Holding AG (OCSAW) Institutional Confidence - TradingKey
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm - GlobeNewswire
Oculis : Minutes of the 2026 Annual General Meeting of Shareholders - marketscreener.com
Oculis Holding AG (OCS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Oculis Holding AG (OCS) And Encourages Shareholders to Connect - ACCESS Newswire
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com
Oculis Holding AG (OCSAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Oculis Holding AG (OCS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment - Streetwise Reports
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles - AOL.com
OCS News | OCULIS HOLDING AG (NASDAQ:OCS) - ChartMill
Oculis shelves FDA filing after phase 3 DME trials miss key vision goals - MSN
Oculis enrolls first patient in licaminlimab PREDICT-1 DED trial - Optometry Times
Oculis to present neuroprotective drug Privosegtor at Clinical Trials Summit 2026 - Pluang
Oculis to present Privosegtor's progress for optic neuritis treatment at Clinical Trials Summit 2026 - Pluang
Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud I - GuruFocus
H.C. Wainwright reiterates Oculis stock rating on trial start - Investing.com UK
H.C. Wainwright reiterates Oculis stock rating on trial start By Investing.com - Investing.com Australia
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - The Manila Times
Oculis Holding AG to Present on Privosegtor at Clinical Trials at the Summit 2026 - Quiver Quantitative
Experimental eye drug Privosegtor aims to protect vision in optic neuritis - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Oculis Holding AG (OCS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Oculis executive and board member buys more company shares - Stock Titan
Oculis randomizes first patient in precision dry eye disease trial - grafa.com
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease - The Manila Times
Oculis Announces First Patient Randomized in PREDICT-1 - GlobeNewswire
New dry eye trial tailors licaminlimab to genes; only 13% see sustained relief - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Oculis to present updates on late-stage eye disease treatments at Goldman Sachs Healthcare Conference - Pluang
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference - The Manila Times
Oculis Holding AG to Provide Update on Late-Stage Portfolio at 47th Annual Goldman Sachs Global Healthcare Conference - Quiver Quantitative
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Oculis Holding AG (OCS) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Price-Driven Insight from (OCS) for Rule-Based Strategy - Stock Traders Daily
2026-06-08 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Oculis Holding AG (OCS) and Encourages Investors to Learn More About the Investigation | NDAQ:OCS | Press Release - Stockhouse
Oculis Holding AG (OCS) Securities Fraud InvestigationLevi & Korsinsky - Morningstar
Oculis Holding Ag (OCS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):